Letter by Maltais et al Regarding Article, 'Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure'

In the article by Uriel et al,1 the authors evaluated a composite end point defined as hemocompatibility-related clinical adverse events (HRAEs) between the HeartMate 3 and the HeartMate II left ventricular assist device. The authors proposed a new hemocompatibility score (HCS) to describe the HRAE burden experienced by patients within the trial period. Mehra et al2 proposed the suggested HCS, which identified the need for a clinical score to quantify a burden of hemocompatibility. The grading system developed by Uriel et al1 relates more to a traditional rating because it consists of individual cutoff points derived from intuitive clinical reasoning. The …